SCHEMBL26075641

SCHEMBL26075641

CCc1cc(-c2ccc(-c3ccc(OC(C)C)cc3)cn2)nc2ccc(C)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.41
▸ ESR2 Q92731 2/20 0.41
▸ ESRRB O95718 1/20 0.41
▸ ESRRA P11474 1/20 0.41
▸ MCL1 Q07820 2/20 0.39
▸ DHODH Q02127 3/20 0.39
▸ MAPT P10636 7/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ EGLN1 Q9GZT9 1/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ PTPN7 P35236 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ DUSP3 P51452 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075632 0.88 MAPT (0.48) ESR1ESR2ESRRBESRRADHODH
SCHEMBL26075631 0.88 ESR1 (0.43) ESR1ESR2ESRRBESRRADHODH
SCHEMBL26075649 0.87 ESRRB (0.39) ESR1ESR2ESRRBESRRADHODH
SCHEMBL26075635 0.86 PLA2G2A (0.44) ESR1ESR2ESRRBESRRADHODH
SCHEMBL26075633 0.86 DHODH (0.45) ESR1ESR2ESRRBESRRADHODH
SCHEMBL26075646 0.85 ESR1 (0.41) ESR1ESR2ESRRBESRRADHODH
SCHEMBL26075644 0.84 PLA2G2A (0.43) ESR1ESR2ESRRBESRRADHODH
SCHEMBL26075665 0.84 ESRRB (0.40) ESR1ESR2ESRRBESRRAMCL1
SCHEMBL26075648 0.83 KDM4E (0.44) ESR1ESR2ESRRBESRRADHODH
SCHEMBL26075645 0.83 KDM4E (0.44) ESR1ESR2ESRRBESRRADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD ESR1 4427/4885ESR2 4530/4885ESRRB 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback